A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)


Tryfonidis K., Basaran G. , Bogaerts J., Debled M., Dirix L., Thery J., ...More

EUROPEAN JOURNAL OF CANCER, vol.53, pp.144-154, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 53
  • Publication Date: 2016
  • Doi Number: 10.1016/j.ejca.2015.10.012
  • Title of Journal : EUROPEAN JOURNAL OF CANCER
  • Page Numbers: pp.144-154

Abstract

Background: Preclinical data suggest that epidermal growth factor receptor (EGFR) inhibitors (e.g. gefitinib) can delay endocrine resistance in breast cancer. A double-blind, placebo-controlled, phase II trial investigated whether adding gefitinib (G) to anastrozole (A) would improve outcome in advanced breast cancer (ABC).